Eli Lilly Says EloraTZP Cut Weight Up To 23.3% Vs. 14.8% For Tirzepatide In Phase 2b Diabetes Trial; Plans Phase 3 In Q4

Benzinga Newsdesk www.benzinga.com Positive 93.6%